Menu
Search
|

Menu

Close
X

Corcept Therapeutics Inc CORT.OQ (NASDAQ Stock Exchange Capital Market)

15.84 USD
+0.07 (+0.44%)
As of 2:02 PM EST
chart
Previous Close 15.77
Open 15.81
Volume 164,435
3m Avg Volume 631,788
Today’s High 16.05
Today’s Low 15.54
52 Week High 25.92
52 Week Low 8.24
Shares Outstanding (mil) 114.12
Market Capitalization (mil) 1,799.74
Forward P/E 54.92
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
106
FY16
81
FY15
50
EPS (USD)
FY17
0.249
FY16
0.069
FY15
-0.062
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
54.92
34.75
Price to Sales (TTM)
vs sector
13.87
8.23
Price to Book (MRQ)
vs sector
20.85
5.26
Price to Cash Flow (TTM)
vs sector
50.75
26.16
Total Debt to Equity (MRQ)
vs sector
0.00
15.44
LT Debt to Equity (MRQ)
vs sector
0.00
12.05
Return on Investment (TTM)
vs sector
60.21
13.63
Return on Equity (TTM)
vs sector
60.21
15.25

EXECUTIVE LEADERSHIP

James Wilson
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Joseph Belanoff
President, Chief Executive Officer, Director, Since 2014
Salary: $615,000.00
Bonus: $400,000.00
Gary Robb
Chief Financial Officer, Secretary, Since 2014
Salary: $374,685.00
Bonus: $146,000.00
Robert Fishman
Chief Medical Officer, Since 2015
Salary: $411,363.00
Bonus: $40,000.00
G. Leonard Baker
Independent Director, Since 1999
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

149 Commonwealth Dr
MENLO PARK   CA   94025-1133

Phone: +1650.3273270

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

SPONSORED STORIES